Core Viewpoint - Ying Sheng Science (00209) proposes a rights issue of 7 shares for every existing share held at a subscription price of HKD 0.14 per share, aiming to raise up to approximately HKD 182 million [1] Summary by Relevant Sections - **Rights Issue Details** - The company plans to issue up to approximately 1.3 billion rights shares, assuming no changes in the number of shares issued before the record date [1] - The subscription price represents a discount of about 23.5% compared to the closing price of HKD 0.183 per share on October 14, 2025 [1] - **Financial Implications** - If fully subscribed, the estimated net proceeds from the rights issue will be approximately HKD 176.5 million, assuming no changes in the number of shares issued before the record date [1]

Core Viewpoint - Ying Sheng Science (00209) announced a proposed rights issue, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share, aiming to raise up to approximately HKD 182 million [1] Group 1: Rights Issue Details - The company plans to issue up to approximately 1.3 billion rights shares, assuming no change in the number of shares issued as of the record date [1] - The subscription price represents a discount of about 23.5% compared to the closing price of HKD 0.183 per share on October 14, 2025 [1] - If fully subscribed, the estimated net proceeds from the rights issue will be approximately HKD 176.5 million, again assuming no change in the number of shares issued as of the record date [1]

Core Viewpoint - Ying Sheng Science (00209.HK) proposes a rights issue to raise up to approximately HKD 182 million by issuing up to 1,299,962,832 rights shares at a price of HKD 0.14 per share, representing a discount of about 23.5% from the last closing price of HKD 0.183 [1] Summary by Categories Rights Issue Details - The company plans to issue a maximum of 1,299,962,832 rights shares to eligible shareholders, with each existing share entitling the holder to one rights share [1] - The estimated net proceeds from the rights issue, assuming full subscription, will be approximately HKD 176.5 million [1] Use of Proceeds - Approximately HKD 116.6 million (about 66.0% of the net proceeds) is intended for loan repayment, covering both principal and interest [1] - About HKD 59.9 million (approximately 34.0% of the net proceeds) will be allocated for general working capital of the group [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 WINSHINE SCIENCE COMPANY LIMITED * 209 (1)建議按於記錄日期 每持有一(1)股現有股份獲發七(7)股供股股份的基準 以悉數包銷方式進行供股； (2)暫停辦理股份過戶登記手續；及 (3)委任獨立財務顧問 本公司財務顧問 建議供股 本公司建議按於記錄日期每持有一(1)股現有股份獲發七(7)股供股股份的基準，以認購 價每股供股股份0.14港元進行供股，以透過向合資格股東發行最多1,299,962,832股供 股股份（假設於記錄日期或之前已發行股份數目並無變動），籌集最多約182.0百萬港元 所得款項總額。 供股僅可提呈予合資格股東，且將不會向不合資格股東（如有）提呈。合資格股東有權 申請超出彼等於供股項下各自配額的供股股份。 假設供股獲悉數認購，則估計供股所得款項淨額將約為176.5百萬港元（假設於記錄日 ...

Group 1 - The company Ying Sheng Science (00209) announced that Mr. Weng Zu Tian will resign as the executive director and CEO effective October 14, 2025 [1] - Ms. Wang Jing Yu has been appointed as the new CEO while continuing her role as the executive director and chairman of the board [1] - Ms. Wang Yu Mei has resigned as an independent non-executive director and will no longer serve on the audit, remuneration, and nomination committees [1] - Mr. Wu Ji Wei has been appointed as an independent non-executive director and will serve on the audit, remuneration, and nomination committees [1]

Core Points - Mr. Weng Zudian will resign as Executive Director and CEO of the company effective October 14, 2025 [1] - Ms. Wang Jingyu has been appointed as the new CEO while continuing her role as Executive Director and Chairman of the Board [1] - Ms. Wang Yumei has resigned as Independent Non-Executive Director and will no longer serve on the Audit, Remuneration, and Nomination Committees [1] - Mr. Wu Jiwei has been appointed as Independent Non-Executive Director and will serve on the Audit, Remuneration, and Nomination Committees [1]

格隆汇10月14日丨瀛晟科学(00209.HK)宣布，自2025年10月14日起，翁祖钿辞任公司执行董事及行政总 裁；公司执行董事兼董事会主席王敬渝已获委任为公司行政总裁；王钰梅辞任公司独立非执行董事及不 再为审核委员会、薪酬委员会及提名委员会各自之成员；及吴继伟已获委任为公司独立非执行董事及审 核委员会、薪酬委员会及提名委员会各自之成员。 ...

瀛 晟 科 學 有 限 公 司 * （於百慕達註冊成立之有限公司） (股份代號：209) 董事名單與其角色及職能 瀛晟科學有限公司董事會（「董事會」）之董事 (「董事」) 成員之最新資料載列如下： 執行董事 王敬渝女士 （主席兼行政總裁） 姚震港先生 WINSHINE SCIENCE COMPANY LIMITED 董事會設立三個委員會。下表提供各董事會成員在這些委員會中所擔任的職位： | 董 | 事 | | | | --- | --- | --- | --- | | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | 董事 | | | | | 王敬渝女士 | – | – | – | | 姚震港先生 | – | – | – | | 林少鵬先生 | – | – | M | | 胡欣綺女士 | C | M | – | | 黃天瑩女士 | M | C | C | | 吳繼偉先生 | M | M | M | 附註： C 有關董事委員會的主席 M 有關董事委員會的成員 香港，二零二五年十月十四日 * 僅供識別 非執行董事 林少鵬先生 獨立非執行董事 胡欣綺女士 黃天瑩女士 吳繼偉先生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 WINSHINE SCIENCE COMPANY LIMITED 瀛 晟 科 學 有 限 公 司 * ( 於百慕達註冊成立之有限公司 ) (股份代號: 209) (1) 執行董事辭任及行政總裁之變更； (2) 獨立非執行董事之變更；及 (3) 董事委員會組成之變更 董事會宣佈，自二零二五年十月十四日起： * 僅供識別 1 王女士的履歷詳情載列如下： 王女士，45 歲，於二零二五年九月加入本集團出任本公司執行董事及董事會主席。 王女士持有中華人民共和國（「中國）西南財經大學經濟學學士學位，主修國際金 融。彼於企業管理及投資方面擁有豐富經驗。王女士曾為信保環球控股有限公司 （一間於香港聯合交易所有限公司（「聯交所」）主板上市之公司）（股份代號： 723）之執行董事及主席，直至二零二五年四月二十五日為止。 於本公告日期及就香港法例第 571 章證券及期貨條例（「證券及期貨條例」）第 XV 部所賦予之涵義而言，王女 ...

近期，瀛晟科学发布公告，李忠海先生(李先生)于2025年9月3日透过Hurray Talent(一间由李先生全资拥 有的公司)出售总数为3739.29万股本公司股份(相当于本公司已发行股本约24.16%)予Peak Access(一间由 王女士全资拥有的公司)。出售事项完成后，本公司的主要股东由 Hurray Talent变更为Peak Access。 香港联交所最新资料显示，10月9日，瀛晟科学(00209)股东将股票由lmagi Brokerage Limited转入富途证 券国际香港，转仓市值249.23万港元，占比6.48%。 ...